Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 30th Preview)
-
FDA regulatory framework shift and user-fee negotiations
A new report says the White House is reviewing the next FDA prescription drug user fee deal covering 2028–2032, setting up a key policy lever for how much authority the agency and industry will share for the drug review pipeline. The decision could influence review timelines and operational targets that drive the next cycle of clinical development planning. Separately, commentary and policy coverage at the Pricing and Contracting USA event highlighted CMS’s push for more direct engagement with pharma on Most Favored Nation (MFN) and related pricing strategy, emphasizing earlier conversations rather than waiting for later compliance questions. Together, the items point to regulators and payers tightening how companies structure market access and early development planning, with engagement moving upstream in both review and pricing.
-
Big pharma–China partnerships in oncology
Pfizer struck a broad oncology collaboration with Innovent Biologics, committing $650 million upfront and up to $9.85 billion in milestones to co-develop a portfolio spanning 12 early-stage and de novo antibody-drug conjugates and multispecifics. Innovent will lead discovery and early development through Phase 1, with Pfizer taking over global development for selected programs. The deal follows similar moves by other large companies, underscoring how global oncology portfolios are increasingly built around China’s ability to run early clinical programs and quickly generate combination-ready assets.
-
ASCO oncology trial updates: pancreatic and melanoma approvals seek momentum
Revolution Medicines began shipping daraxonrasib to physicians and patients under an FDA-authorized early access program for pancreatic cancer. The company said patients have been seeking access since results were reported in mid-April, when the Phase 3 trial showed near-doubling of overall survival versus standard chemotherapy. In parallel at ASCO, Replimune announced it has aligned with the FDA to resubmit its melanoma BLA for RP-1 after two prior rejections, positioning the therapy for an “urgent” review on resubmission. The combined moves highlight how late-stage wins are quickly translated into expanded pathways, while regulators still gatekeep evidence quality for approval.
-
Late-stage hematology gains: multiple myeloma CELMoD and PARP–ARPI strategy readouts
Bristol Myers Squibb presented Phase 3 SUCCESSOR-2 data showing mezigdomide improved progression-free outcomes in relapsed/refractory multiple myeloma when added to carfilzomib and dexamethasone. The regimen cut the risk of disease progression or death by 52% versus the background therapy, and BMS reported a median PFS of 18 months versus 8.3 months. Separately, Pfizer disclosed detailed Phase 3 TALAPRO-3 results of TALZENNA (talazoparib) plus XTANDI (enzalutamide) in HRR gene-mutated metastatic castration-sensitive prostate cancer. The combination reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI, with three-year rPFS estimated at 77% versus 56%.
-
ASCO diagnostic evidence standards: MCED Galleri not recommended
ASCO said it will not recommend Grail’s Galleri multi-cancer early detection test for screening guidelines after reviewing new trial data. The coverage highlighted that the NHS-Galleri randomized study failed to meet its primary endpoint, a key evidentiary bar for reducing the incidence of multiple late-stage cancers. ASCO’s decision adds another institutional checkpoint in the MCED debate, even as discussion remains around secondary signals such as stage IV reduction and earlier detection patterns.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.